scholarly journals Topical Treatment of Truncal Acne with Tretinoin Lotion 0.05% and Azelaic Acid Foam

2020 ◽  
Vol 2020 ◽  
pp. 1-5 ◽  
Author(s):  
Sharleen St. Surin-Lord ◽  
Judi Miller
Keyword(s):  
Azelaic Acid ◽  
Oral Treatment ◽  
Acne Vulgaris ◽  
Topical Therapy ◽  
Treatment Options ◽  
Case Series ◽  
Oral Antibiotics ◽  
Gastrointestinal Microbiome ◽  
The Face ◽  
Extensive Body

Truncal acne is present in approximately half of all patients with facial acne but is also occasionally seen in isolation. Important considerations when selecting treatment options for adult female acne, whether on the face, back, chest, or shoulders, include patient compliance, treatment response time, tolerability of the treatment, and psychosocial impact of the disease. Oral antibiotics are widely prescribed for truncal acne due to the challenges of applying topical therapy to such an extensive body surface area. In cases of severe inflammatory and nodular acne vulgaris, this may be a reasonable consideration; however, oral antibiotics should only be used for short durations. Overprescription contributes to microbial resistance and may cause disruption of the gastrointestinal microbiome. In many cases of mild, moderate, or even severe truncal acne, combinations of topical therapies may be valid alternatives. The introduction of foam formulations with enhanced percutaneous absorption and tretinoin lotion formulations that incorporate moisturizing/hydrating agents challenges the previously held idea that effective and tolerable treatment of truncal acne requires oral treatment. This case series describes four female African-American patients with truncal acne successfully treated with a combination of tretinoin lotion 0.05% and azelaic acid 15% foam.

scholarly journals Efficacy and Safety of Azelaic Acid Nanocrystal-Loaded In Situ Hydrogel in the Treatment of Acne Vulgaris

Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 567
Author(s):  
Ivona Tomić ◽  
Sandra Miočić ◽  
Ivan Pepić ◽  
Dubravka Šimić ◽  
Jelena Filipović-Grčić
Keyword(s):  
Azelaic Acid ◽  
Controlled Trial ◽  
Acne Vulgaris ◽  
Topical Therapy ◽  
Adverse Event Rate ◽  
Double Blind ◽  
Inflammatory Lesions ◽  
First Choice ◽  
In Situ Hydrogel

Acne vulgaris is a common, multifactorial, inflammatory skin disease affecting the pilosebaceous unit. Topical therapy is the first choice in the treatment of mild to moderate acne, and azelaic acid (AZA) is one of the most commonly used drugs. The aim of this study was to evaluate the safety and efficacy of a low-dose azelaic acid nanocrystal (AZA-NC) hydrogel in the treatment of mild to moderate facial acne. The study was designed as a double-blind, randomized controlled trial. Patients were randomized to treatment with AZA-NC hydrogel, 10%, or AZA cream, 20%, administered in quantities of approximately 1 g twice daily for 8 weeks. Efficacy of therapy was measured by the number of lesions and safety by the frequency and severity of adverse events. At week 8, the success rate of treatment with AZA-NC hydrogel, 10%, was 36.51% (p < 0.001) versus 30.37% (p < 0.001) with AZA cream. At week 8, treatment with AZA-NC hydrogel, 10%, resulted in a significant reduction in total inflammatory lesions from baseline of 39.15% (p < 0.001) versus 33.76% (p < 0.001) with AZA cream, and a reduction in non-inflammatory lesions from baseline of 34.58% (p < 0.001) versus 27.96% (p < 0.001) with AZA cream, respectively. The adverse event rate was low and mostly mild.

scholarly journals Microneedling Radiofrequency for Acne Vulgaris and Post-Acne Scarring: A Case Report

2022 ◽  
Vol 6 (3) ◽  
pp. 1443-1445
Author(s):  
Vesri Yossy ◽  
Wydya Yenny ◽  
Lilik Norawati
Keyword(s):  
Case Report ◽  
Combination Therapy ◽  
Acne Vulgaris ◽  
Topical Therapy ◽  
Skin Surface ◽  
Therapeutic Modalities ◽  
Dermatological Examination ◽  
Acne Scars ◽  
The Face ◽  
Acne Scarring

Background: There are various therapeutic modalities for acne and post acne scarring, but the best option is to have a safe, effective with affordable cost such as monotherapy or combination therapy. One of the recommended combination therapy for acne vulgaris with atrophic acne scars is microneedling radiofrequency which can improve skin structure. Case report: A 25 year old male with moderate comedonal acne vulgaris and severe scarring. The patient came with complaints of uneven skin surface on both cheeks, forehead and chin which had been felt to increase since 3 years ago. The appearance of acne on the face has been felt since 12 years ago. The patient's parents and sister also had acne complaints. On dermatological examination, on the forehead, temples, cheeks, nose and chin found blackheads, whiteheads, papules, hyperpigmented macules, multiple atrophic acne scars. The treatment choice for this patient is microneedling radiofrequency in combination with topical therapy. Discussion: The combination of microneedling with radiofrequency is one of the therapeutic modalities for acne vulgaris and also post-acne scarring with minimal side effects. In the evaluation for 2 weeks after the procedure, this patient did not complaint of any adverse events.

scholarly journals Hydrogel composite containing azelaic acid and tea tree essential oil as a therapeutic strategy for Propionibacterium and testosterone-induced acne

2021 ◽  
Author(s):  
Alpna Bisht ◽  
Chetna Hemrajani ◽  
Charul Rathore ◽  
Tania Dhiman ◽  
Rajan Rolta ◽  
...  
Keyword(s):  
Azelaic Acid ◽  
Ternary Phase Diagram ◽  
Acne Vulgaris ◽  
Topical Therapy ◽  
Wistar Rat ◽  
Bacterial Strains ◽  
Uniform Size ◽  
Tea Tree ◽  
Hydrogel Composite

AbstractAzelaic acid (AzA) is a USFDA bioactive prescribed against acne vulgaris. It possesses delivery challenges like poor aqueous solubility, low skin-penetrability, and dose-dependent side effects, which could be overcome by its synergistic combination with tea tree oil (TTO) as a microemulsion (ME)-based hydrogel composite. AzA-TTO ME was prepared to employ pseudo-ternary phase diagram construction. The best AzA-TTO ME was of uniform size (polydispersity index < 0.7), nano-range (~357.4 ± 2% nm), transmittance (> 90%), and negative zeta potential (−1.42 ± 0.25% mV) values. ME hydrogel composite with optimum rheological and textural attributes showed better permeation, retention, and skin-compliant characteristics, vis-a-vis marketed formulation (Aziderm™) when evaluated in Wistar rat skin. In vitro antibacterial efficacy in bacterial strains, i.e., Staphylococcus aureus, Propionibacterium acne, and Staphylococcus epidermidis, was evaluated employing agar well plate diffusion and broth dilution assay. ME hydrogel has shown an increase in zone of inhibition by two folds and a decrease in minimum inhibitory concentration (MIC) by eightfold against P. acnes vis-a-vis AzA. Finally, ME hydrogel composite exhibited a better reduction in the papule density (93.75 ± 1.64%) in comparison to Aziderm™ 72.69 ± 4.67%) on acne as developed in rats by inducing testosterone. Thus, the developed AzA-TTO ME hydrogel composite promises an efficacious and comparatively safer drug delivery system for the topical therapy of acne vulgaris. Graphical abstract

scholarly journals Infantile acne is a medical problem that calls for therapy

2022 ◽  
pp. 49
Author(s):  
◽  
◽  
◽  
Keyword(s):  
Acne Vulgaris ◽  
Case Series ◽  
Medical Problem ◽  
Response To Treatment ◽  
Therapeutic Trial ◽  
Hormonal Changes ◽  
Female Ratio ◽  
Uncommon Disease ◽  
The Face ◽  
Clinical Scoring

Background: Acne vulgaris of infants is a well-recognized medical and cosmetic problem as it may cause severe scarring of the face. Hence medical treatment is essentially needed. Objective: To record all patients with infantile acne vulgaris and to do full demographic and clinical evaluation. Patients and methods:This is case series clinical descriptive study with interventional therapeutic trial that included all patients with infantile acne vulgaris that were seen during the period from Jan 2021 – September 2021 years. All demographic and clinical features were recorded. The clinical scoring of acne severity was done as follow:mild when the rash was mainly comedones,moderate mainly papules and pustules and severe mainly nodules and scarring. Any triggering factors were recorded including hormonal changes. Therapy was started by giving topical 2% clindamycin twice a day and oral trimethoprim-sulfamethoxazole suspension one teaspoonful twice a day for 1-2 months. Results: This study included 28 patients with infantile acne, with 19(67.86%) males and 9(32.14%) females with male to female ratio;2.1. The age of patients ranged from 1-24 months, with a mean 14.6 ±6.1.The duration of rash was ranged from 4-8 weeks. The commonest sites affected were cheeks in 27(96.4%) cases, followed by forehead in 8 (28.6%), then chin in 6 (23.1%), and nose 6 (23.1%) of the cases. Scoring of severity of acne showed moderate in 13(46.4%), followed by mild in 9 (32.1%), and sever in 6 (21.4%). The response to treatment was complete clearance in 15(53.6%) and partial response in 13(46.4%) of the patients while no adverse effects were observed. Conclusions: Infantile acne is not uncommon disease among infants where medical therapy is essentially needed especially in severe cases as to prevent facial scarring. Early diagnosis and treatment with oral trimethoprim-sulfamethoxazole suspension and topical 2% clindamycin lotion is an effective mode of therapy.

scholarly journals Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis

2017 ◽  
Vol 9 (2) ◽  
pp. 141-145 ◽  
Author(s):  
Ganesh Pai ◽  
Anusha H. Pai
Keyword(s):  
Psoriatic Arthritis ◽  
Biological Therapy ◽  
Human Lymphocytes ◽  
Systemic Disease ◽  
Topical Therapy ◽  
Treatment Options ◽  
Case Series ◽  
Poor Responders ◽  
Rapid Action ◽  
Long Time

Psoriasis is a chronic, relapsing, inflammatory, immune-mediated systemic disease with mainly skin and joint manifestations. The available treatment options to cure psoriasis include topical therapy, phototherapy, and biological therapy. Biological therapy has become a promising option due to the rapid action and less adverse effects associated with its use. The newly developed biologic itolizumab is a humanized recombinant anti-CD6 monoclonal antibody of IgG1 isotype that binds to domain 1 of CD6, thereby immunomodulating human lymphocytes without interfering with the binding of CD6 to the activated leukocyte-cell adhesion molecule. In this case series, a total of 5 patients with chronic plaque psoriasis were treated with itolizumab. They exhibited a rapid PASI 75 response after 4 doses of itolizumab infusion. The patients were poor responders to methotrexate and/or cyclosporine therapy for a long time. All infusions were well tolerated by all patients with no adverse reactions or infections during the treatment period. Itolizumab can be a good option for management of psoriasis and psoriatic arthritis.

scholarly journals Ceftriaxone for the Treatment of Chronic Bacterial Prostatitis: A Case Series and Literature Review

Antibiotics ◽  
2022 ◽  
Vol 11 (1) ◽  
pp. 83
Author(s):  
Sander G. Kuiper ◽  
Maarten Ploeger ◽  
Erik B. Wilms ◽  
Marleen M. van Dijk ◽  
Emiel Leegwater ◽  
...  
Keyword(s):  
Literature Review ◽  
Oral Treatment ◽  
Treatment Options ◽  
Case Series ◽  
Chronic Bacterial Prostatitis ◽  
E Coli ◽  
Early Withdrawal ◽  
Bacterial Prostatitis ◽  
Appropriate Treatment

Chronic bacterial prostatitis is increasingly difficult to treat due to rising antimicrobial resistance limiting oral treatment options. In this case series, 11 men with CBP (including patients with urological comorbidities) due to multi-resistant E. coli were treated with once-daily ceftriaxone intravenously for 6 weeks. Nine patients were clinically cured at 3 months follow up. No early withdrawal of medication due to side effects occurred. A literature review was conducted to describe the prostate pharmacokinetics of ceftriaxone and its use in prostatic infection. In conclusion, ceftriaxone can be considered an appropriate treatment of chronic bacterial prostatitis.

scholarly journals Resurfacing of facial acne scars with pulsed carbon dioxide laser: a case series of 10 patients

2020 ◽  
Vol 7 (1) ◽  
pp. 113
Author(s):  
Anil P. Gosavi ◽  
Ravindranath B. Chavan ◽  
Darshana R. Kundale ◽  
Neelam Bhatt
Keyword(s):  
Carbon Dioxide ◽  
Carbon Dioxide Laser ◽  
Acne Vulgaris ◽  
Treatment Options ◽  
Case Series ◽  
Laser Resurfacing ◽  
Acne Scars ◽  
Common Skin ◽  
Carbon Dioxide Co2 ◽  
Facial Acne

<p class="abstract">Acne vulgaris is a common skin disorder affecting 80% of people between 11-30 years of age with many experiencing some degree of scarring. Pulsed wave carbon dioxide (CO2) laser resurfacing is a recent addition in armamentarium of treatment options for acne scars. This study focuses on one of the most common type of acne complication - atrophic scars treated with pulsed wave carbon dioxide laser. To evaluate efficacy of pulsed carbon dioxide laser for treatment of mild to moderate atrophic facial acne scars. 10 subjects (6 male and 4 females, aged 22-35 years) with skin type III-V and atrophic acne scars were treated with 4 sessions of carbon dioxide non-ablative laser resurfacing on 6 weeks interval. 7 out of 10 subjects in our study perceived an excellent to good improvement with 2 patients showing fair improvement and 1 patient with no improvement. Adverse effects were limited to prolonged erythema (two patients), and post-inflammatory hyperpigmentation (three patient). Excellent to good clinical improvement observed in 70% of patients with acne scars. This underscore pulsed carbon dioxide laser’s effectiveness in the treatment of mild to moderate atrophic acne scars.</p>

In-block lateralization as a new technique for mobilization of the inferior alveolar nerve: a technique case series

2020 ◽  
Author(s):  
Marcos Augusto Tomazi ◽  
Alexandre da Silveira Gerzson ◽  
Angelo Menuci Neto ◽  
André Luciano Pasinato da Costa
Keyword(s):  
Treatment Options ◽  
Inferior Alveolar Nerve ◽  
Case Series ◽  
New Technique ◽  
Autogenous Bone ◽  
Minimal Risk ◽  
Short Implants ◽  
Bone Atrophy ◽  
A New Technique ◽  
Number Of Treatment

The edentulous atrophic posterior mandible is often a great challenge for implant rehabilitation. Although a number of treatment options have been proposed, including the use of short implants and surgical grafting techniques, in cases of severe bone atrophy, techniques for mobilization of the inferior alveolar nerve (IAN) have been shown to be efficient, with good results. Four female patients underwent IAN lateralization for prosthetic rehabilitation of the posterior mandible from 2013 to 2019, with 1 year to 5 years and 4 months of follow-up. This case series describes a new technique for mobilization of the IAN, named in-block lateralization, to facilitate access to the IAN and to reduce nerve manipulation. The implant is immediately installed (allowing nerve lateralization in unitary spaces) and the original mandibular anatomy is restored with autogenous bone from the original bed during the same surgical procedure. When well indicated and well performed, this new approach provides better and easier visualization of the IAN as well as safer manipulation aiming to achieve good results for implant stability and minimal risk of neurosensory disturbances, allowing rehabilitation even in unitary spaces.

Antiretroviral Treatment-Associated Labia Majora Lipohypertrophy: A Rare Case and Plastic Surgical Treatment Options

2017 ◽  
Vol 2 (1) ◽  
pp. 43
Author(s):  
Akmal Hisham ◽  
Devananthan Ilenghoven ◽  
Wan Syazli Wan Ahmad Kamal ◽  
Salina Ibrahim ◽  
Shah Jumaat Mohd Yussof
Keyword(s):  
Highly Active Antiretroviral Therapy ◽  
Daily Living ◽  
Treatment Options ◽  
Hiv Positive ◽  
Highly Active ◽  
Labia Majora ◽  
The Face ◽  
Central Fat

The emergence of highly active antiretroviral therapy (HAART) has revolutionized the prognosis of HIV-infected patients. However, the extended use of HAART is associated with a disfiguring complication termed lipodystrophy, a disorder of body fat maldistribution causing peripheral fat loss (lipoatrophy) and central fat accumulation (lipohypertrophy). Lipoatrophy commonly affects the face, legs, buttocks and arm, whilst lipohypertrophy frequently favours the abdomen, breast and dorsocervical region. To our knowledge, we present only the second documented case in the literature of a labia majora lipohypertrophy in a HIV-positive patient receiving long-term HAART. The severity of labial abnormality caused significant physical and functional morbidities. Labiaplasty with dermolipectomy of the labia majora and excisional lipectomy of the mons pubis was successfully performed. At a 6-month follow-up, patient had no recurrence with resolution of symptoms and resumption of normal activities of daily living (ADL).

Sign in / Sign up

Export Citation Format

Share Document